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Abstract Cellular senescence is now considered as a
major mechanism in the development and progression
of various diseases and this may include metabolic
diseases such as obesity and type-2 diabetes. The
presence of obesity and diabetes is a major risk factor
in the development of additional health conditions,
such as cardiovascular disease, kidney disease and
cancer. Since senescent cells can drive disease devel-
opment, obesity and diabetes can potentially create an
environment that accelerates cell senescence within
other tissues of the body. This can consequently
manifest as age-related biological impairments and
secondary diseases. Cell senescence in cell types
linked with obesity and diabetes, namely adipocytes
and pancreatic beta cells will be explored, followed by
a discussion on the role of obesity and diabetes in
accelerating ageing through induction of premature
cell senescence mediated by high glucose levels and
oxidised low-density lipoproteins. Particular emphasis
will be placed on accelerated cell senescence in
endothelial progenitor cells, endothelial cells and
vascular smooth muscle cells with relation to cardio-
vascular disease and proximal tubular cells with
relation to kidney disease. A summary of the potential
strategies for therapeutically targeting senescent cells
for improving health is also presented.
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Introduction
The senescent state is a stress response which ensures
that cell damage is removed through activation of the
immune system. During this response, often induced
by persistent DNA damage, cells lose their ability to
proliferate; ensuring cells do not become cancerous. In
addition, senescent cells develop an altered secretome
consisting of pro-inflammatory factors, growth factors
and proteases. Thus, senescent cells appear to mimic a
wound healing response. Components of the senescent
secretome function in attracting immune cells for the
elimination of these damaged cells, thereby promoting
the restoration of tissue homeostasis (Burton and
Faragher 2015). However, during biological ageing
and disease processes, senescent cells can accumulate.
It is suspected that an ageing immune system
(immunosenescence) may contribute to the
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accumulation of senescent cells through failure to
remove them.
Metabolic diseases are associated with a disruption
in normal cell metabolism, the process of converting
food to energy on a cellular level. Such diseases
impact the capacity of the cell to undertake essential
biochemical reactions that involve the transport or
processing of proteins, carbohydrates and lipids. Both
obesity and type 2 diabetes are known to alter cell
metabolism (Singla et al. 2010). Diabetes is a global
health problem, estimated to be affecting 422 million
people worldwide in 2014 and predicted to become the
seventh leading cause of death in 2030 (World Health
Organisation). Therefore, understanding the mecha-
nisms promoting metabolic diseases and the biological
consequence of such diseases is essential for the
development of novel therapeutics. Cellular senes-
cence may be one mechanism contributing to obesity
and diabetes. In addition, the presence of obesity and
diabetes can promote secondary diseases such as
cardiovascular disease (CVD) and kidney disease,
potentially through induction of premature cell senes-
cence in other tissues. As such, the mechanisms and
processes by which obesity and diabetes promote
premature senescence will be the focus of this review.
Cellular senescence as a mechanism of ageing
and disease
Senescent cells have been associated with many age-
related diseases and the subject has been extensively
reviewed in recent years (Burton 2009; Childs et al.
2015; Mun˜oz-Espı´n and Serrano 2014; Ovadya and
Krizhanovsky 2014; Sikora et al. 2014; van Deursen
2014) and so will not be explored here in depth.
Instead, the underlying conceptual mechanisms as to
how senescent cells could cause a decline in biological
function underlying ageing and disease will be
discussed (Fig. 1).
There are a number of mechanisms by which the
senescent state can contribute to both natural ageing
and accelerated ageing, both of which can manifest as
age-related disease and as such, ‘‘ageing’’ and ‘‘age-
related disease’’ can be considered as indistinguish-
able processes (reviewed in Faragher 2015). Natural
ageing here is referred to as the gradual decline in
biological function over the lifespan of an organism,
whereas accelerated ageing likely involves the same
processes but at a quicker rate due to additional
stresses such as smoking, exposure to toxins,
chemotherapy, high-fat diet and the presence of
infectious disease. Accelerated ageing is more likely
to impact certain tissues/organs rather than the organ-
ism as a whole. For example, chronic obstructive
pulmonary disease (COPD) caused by smoking is
probably the result of accelerated lung ageing induced
by cigarette smoke (Ito and Barnes 2009; Mercado
et al. 2015). The senescent state has the potential to
induce biological dysfunction through their (1) inabil-
ity to proliferate, (2) loss of normal cell function, (3)
the secretion of pro-inflammatory factors, (4) altering
the behaviour of neighbouring cells and (5) protease-
mediated degradation of extracellular components
(Fig. 1).
Irreversible proliferative arrest
Cell turnover is essential for replacement of damaged/
lost cells which occurs throughout the lifespan of an
organism. As such, the presence of permanently
arrested senescent cells would consequently reduce
the number of cells capable of regenerating new tissue,
more so if stem/progenitor cell senescence occurs.
Such a decline in the regenerative capacity of cells
would not only impact growth competent somatic
tissues, but also post-mitotic tissues that rely on these
growth competent cells to maintain their normal
function.
Loss of cell function
When a cell becomes senescent they can no longer
undertake their original function effectively, poten-
tially leading to a decline in overall tissue function.
This may partly be due to drastic alterations in gene
expression, some of which are senescent specific,
some of which may be cell type specific. Furthermore,
it has been speculated that senescent cells undergo
promiscuous gene expression as a consequence of
stochastic activation of genes due to continuous
chromatin remodelling (reviewed in Burton and
Faragher 2015). Examples of senescence-mediated
functional cellular decline include (1) the inability of
senescent vascular endothelial cells to generate nitric
oxide required for regulating coronary vascular tone
(Matsushita et al. 2001), (2) impaired insulin secretion
by senescent pancreatic beta cells required for
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regulating glucose levels (Sone and Kagawa 2005), (3)
reduced vascular tone due to the pro-calcificatory
phenotype of senescent vascular smooth muscle cells
(Burton et al. 2009; Nakano-Kurimoto et al. 2009) and
(4) impaired adipogenesis due to a decline in adi-
pogenic differentiation genes in senescent adipose
progenitor cells (Mitterberger et al. 2014). Senescence
research to date has primarily been focused on
phenotypic similarities between different cell types
rather than alterations, particularly functional abnor-
malities, which may be specific to certain senescent
cell populations. An understanding of these senescent
cell type specific responses will likely provide further
insight with regard to their relationship to disease
processes.
Pro-inflammatory secretome
If senescent cells persist in tissues, continuous secre-
tion of pro-inflammatory factors have the potential to
induce tissue injury that ultimately manifests as
disease. Persistent inflammation can cause tissue
injury by a number of routes, including; inducing cell
death, elevating ROS, persistent activation of immune
cells and altering the tissue microenvironment (Mittal
et al. 2014; Wallach et al. 2014). Some studies also
suggest that inflammatory factors such as cytokines
may also accelerate cellular senescence in neighbour-
ing cells (Acosta et al. 2013). Due to the potential
detrimental consequence of senescence-mediated
inflammation, a number of studies have focused their
efforts on identifying molecular pathways that could
be targeted to inhibit this inflammatory response
(Alimbetov et al. 2016; Laberge et al. 2012b; Xu et al.
2015b).
Altering the behaviour of neighbouring cells
Pro-inflammatory factors in addition to other secretory
components associated with cell senescence likely
impact the behaviour/function of neighbouring cells
via paracrine signalling. One of the more widely
studied aspects of this senescence-mediated paracrine
response is its ability to stimulate cell proliferation and
invasion in premalignant and malignant cells (Krtolica
et al. 2001; Laberge et al. 2012a) in addition to
promoting age-related hyperplasia (Castro et al. 2003;
Vital et al. 2014) and angiogenesis (Coppe´ et al. 2006).
During normal wound healing, stimulated prolifera-
tion and angiogenesis by transient senescent cells is
likely beneficial, but aberrant signalling via persistent
senescent cells consequently stimulates unwarranted
proliferation and cell behaviour associated with dis-
ease. Whilst direct transfer of proteins and cell
organelles from senescent cells to NK cells appear to
facilitate NK activation as mentioned previously
(Biran et al. 2015), the same processes could poten-
tially be hijacked by pre-cancerous and cancer cells to
promote cancer development/progression through
obtaining valuable cell resources (Biran and Krizha-
novsky 2015). Senescent cells could also potentially
alter the behaviour of neighbouring cells via secretion
of extracellular vesicles such as exosomes that may
contain regulatory components such as microRNAs
Fig. 1 Mechanisms by which senescent cells promote ageing and age-related disease
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(Xu and Tahara 2013). Future research will likely
uncover additional processes whereby senescent cells
can communicate and influence neighbouring cells.
Degradation of extracellular proteins
The final process by which senescent cells could
promote age-related disease is via the degradation of
extracellular proteins. The extracellular matrix (ECM)
is essential for normal intercellular communication
required to maintain optimal tissue homeostasis and
for providing structural and biochemical support to
cells (Cox and Erler 2011). As such, ECM degradation
by proteases can potentially disrupt normal tissue
function that manifests as disease. Senescent cells
often secrete proteases, particularly matrix metallo-
proteases (MMPs) as part of their wound healing
response and as such likely contribute to beneficial
physiological processes in the short-term (Caley et al.
2015). However, if senescent cells persist in tissues
and they continue to secrete these proteases, they
likely contribute to pathological processes, including
impaired wound healing (Mulder and Vande Berg
2002). One of differences between acute and chronic
wound environments appears to be an elevation in
protease production in chronic wounds (McCarty and
Percival 2013) suggesting an age-related accumula-
tion of senescent cells in tissues could impair the
wound response commonly observed in later life.
Cellular senescence as a driver of metabolic
diseases
Senescent cells have been shown to play a role in the
development and progression of numerous diseases
and obesity and type 2 diabetes are not an exception.
Before discussing the potential role of these metabolic
diseases as drivers of cell senescence, a brief overview
of cell senescence as a mechanism promoting meta-
bolic diseases is warranted.
Cellular senescence in adipose tissue
Obesity is the predominant risk factor for development
of type-2 diabetes. This suggests that biological
changes associated with obesity drive the develop-
ment of type-2 diabetes. Obesity is linked with an
increase in the adipose tissue mass, consisting
primarily of adipocytes which specialise in storing
energy as fat. There are a number of studies suggesting
senescent cells in adipose tissue plays a role in the
development of insulin resistance and diabetes.
For example, it was found that excessive calorie
intake promoted oxidative stress in the adipose tissue
of mice with features of type-2 diabetes and the
appearance of senescent markers such as p53,
increased senescence-associated beta galactosidase
activity (SA-b-Gal) and pro-inflammatory cytokines
(Minamino et al. 2009). Furthermore, the upregulation
of p53 in adipose tissue was shown to promote insulin
resistance, whereas p53 inhibition reduced senescent
markers and improved insulin resistance. In addition,
markers associated with cellular senescence were also
observed to be elevated in adipose tissue obtained
from individuals with diabetes. In another study using
a mouse model to generate elevated DNA damage and
cellular senescence in adipose tissue, Chen et al. 2015
demonstrated that such mice develop obesity and
glucose intolerance. p53 inhibition using pifithrin-a
lead to a reduction in adipocyte senescence and
reduced metabolic abnormalities. Interestingly, Mon-
ickaraj et al. (2013) reported that senescent adipocytes
appear to decrease the levels of adiponectin, an
adipocyte specific protein involved in the metabolism
of lipids and glucose. These cells also demonstrated
reduced glucose uptake, likely a response of reduced
adiponectin levels.
Another mechanism by which senescent cells can
promote biological decline in adipose tissue is by
preventing adipogenic differentiation. It has been
demonstrated that senescent adipose-derived stromal/
progenitor cells in response to an adipogenic hormone
cocktail show reduced expression of key adipogenic
regulators and impaired expression of adipogenic
differentiation genes, including adiponectin (Mitter-
berger et al. 2014). In another study, Zhao and Chen
investigated whether elevated lipopolysaccharides
(LPS) which has been associated with obesity,
contribute to induction of cellular senescence and
impaired adipogenic capacity (Zhao and Chen 2015).
Stromal-vascular cells isolated from adipose tissue of
mice subjected to LPS underwent induction of cellular
senescence and a decrease in expression of adipocyte
marker genes. Inhibiting LPS-induced NF-kB activa-
tion, a known regulator of the senescent secretome, did
not rescue the impaired adipogenesis. More recently,
Xu et al. (2015a) found that senescent human fat
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progenitor cells secrete activin A which can directly
inhibit adipogenesis in non-senescent progenitors.
Clearance of senescent cells using naturally aged
INK-ATTAC mice reduced circulating activin A and
enhanced adipogenesis. Collectively, these studies
suggest that senescent cells within adipose tissue may
promote the development of obesity, diabetes and age-
related dysfunction.
Cell senescence in pancreatic beta cells
In addition to senescent cells in adipose tissue, a
limited number of studies have focused on the
potential role of the senescent state in pancreatic beta
cells. Since pancreatic beta cells play an essential role
in insulin production, a dysfunctional response in this
cell type unsurprisingly has been contributed to the
pathogenesis of diabetes. Pancreatic cell dysfunction
leading to impaired insulin secretion has been asso-
ciated with a variety of factors including, but not
limited to, increased inflammation, autoimmunity,
oxidative stress and ER stress (Cerf 2013). With the
current understanding of the senescent response as
more than simply irreversible proliferative arrest,
many of these contributing factors can be associated
with induction of cellular senescence, although it
would be unwise to assume that this is the only
mechanism. Senescent cells are known to be pro-
inflammatory, induce an immune response (likely
resembling autoimmunity), display elevated levels of
ROS (possibly a response to metabolic changes and
mitochondria dysfunction) and in a number of cases,
ER stress has been reported (Burton and Faragher
2015).
One of the first studies to suggest that senescent
pancreatic beta cells may play a role in the pathogen-
esis of type-2 diabetes was a study undertaken by Sone
and Kagawa using high-fat diet induced diabetic mice
(Sone and Kagawa 2005). Following 12 months of
high-fat diet, the proliferating fraction of beta cells
determined by Ki67 staining was reduced to one-third
compared to the control group in conjunction with an
elevation (4.7-fold) in SA-beta-Gal positive cell
staining. Because these changes were associated with
a decrease in insulin production, it was speculated that
cellular senescence contributes to the pathogenesis of
diet-induced diabetes. Krishnamurthy went on to
demonstrate that the senescence effector p16INK4A is
elevated in pancreatic islets during normal ageing in
mice (Krishnamurthy et al. 2006). Furthermore, the
overexpression of p16INK4A comparable to normally
aged mice using transgenic mice decreased islet
proliferation, consequently impairing the regenerative
capacity of beta cells in response to a specific beta cell
toxin.
Recently, the forced induction of proliferative
arrest in pancreatic beta cells via experimental over-
expression of p16INK4A was shown to enhance insulin
secretion which improved glucose homeostasis in
diabetic mice (Helman et al. 2016). However, cellular
senescence is more complex than irreversible prolif-
erative arrest alone. Through experimentally evoking
a single senescent phenotype (cell-cycle arrest) as was
undertaken in this instance, there is a risk of generating
a ‘‘non-physiological’’ response leading to misleading
interpretations. Since the DDR likely regulates many
aspects of the senescent phenotype, including the pro-
inflammatory secretome and the upregulation of
immune ligands, in the absence of DNA damage,
many aspects of the senescent phenotype that may
normally promote a dysfunctional cell may not be
presented. It is plausible that proliferative arrest alone
allows pancreatic beta cells to function normally,
albeit proliferation, causing these cells to grow in size.
In response to an increase in cell size typical of
senescent cells, all aspects of cellular physiology will
also likely increase as a compensatory mechanism and
this would include insulin secretion. As such, the
authors advise caution when interpreting data from
‘‘senescent’’ models that utilise the overexpression of
cyclin dependent kinase inhibitors such as p16INK4A
and p21WAF-1. Whether this response occurs naturally
in vivo has yet to be determined and more research is
required to further evaluate the findings of this study.
Despite the potential involvement of senescent
pancreatic beta cells in diabetes, little in-depth
research has been undertaken to investigate the
mechanistic relationship between senescent cells and
diabetes. Future advances focused on specifically
eliminating senescent cells from tissues will allow
researchers to directly assess the involvement of
senescent cells in the pathogenesis in diabetes.
Metabolic diseases as inducers of cell senescence
Metabolic diseases such as obesity and diabetes
accelerate biological ageing (Bonomini et al. 2015;
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Horvath et al. 2014; Rana et al. 2014; Mooradian
1988; Ronan et al. 2016; Yang et al. 2009) and
consequently the appearance of age-related diseases,
notably, cardiovascular disease (CVD) and kidney
disease (Grundy et al. 1999; Reidy et al. 2014). One
mechanism by which the ageing process could be
accelerated is through premature induction of the
senescent state (Fig. 2).
Cardiovascular disease (CVD)
Endothelial progenitor cells
The repair of damage to the endothelial is essential in
preventing the formation of atherosclerosis. Endothe-
lial progenitor cells (EPCs) are immobilised from the
bone marrow into the peripheral blood in response to
vascular damage via the release of growth factors (of
which VEGF appears to be an important factor),
cytokines and chemokines (Young et al. 2007).
However, the number and function of EPCs have
been shown to be negatively correlated with various
atherosclerotic risk factors and may be a consequence
of accelerated senescence in EPCs (Yang et al. 2008).
In particular, hypertension, often a consequence of
obesity, may accelerate EPC senescence. Imanishi
et al. (2005) have shown that the levels of SA-b-Gal
positive EPCs increases and telomerase activity
decreases in patients with hypertension and that
induction of cell senescence was due to angiotensin
II mediated oxidative stress. Zhou et al. (2010) later
demonstrated that EPC senescence during hyperten-
sion may also be related to a reduction in calcitonin
gene-related peptide (CGRP). Whilst these studies are
limited and do not fully characterise the senescent
state in EPCs, they do provide a basis to explore the
connection between hypertension and EPC senescence
in further depth. Although the mechanisms promoting
EPC senescence during hypertension is unknown, it
can be speculated that high blood pressure increases
damage and loss of cells from the vasculature,
resulting in an increase turnover of EPCs and conse-
quently induction of replicative senescence.
The presence of diabetes is also a major risk factor
in the development of CVD (Fadini et al. 2005) and
may also accelerate the appearance of senescent EPCs.
Diabetes is associated with high blood glucose levels
which may contribute to premature cell senescence.
Kuki et al. (2006) demonstrated that EPCs cultured
under high glucose levels undergo accelerated senes-
cence. Chen et al. (2007) also demonstrated that high
glucose induces a senescent state in EPCs associated
with a decrease in nitic oxide synthase activity.
Furthermore, this study also demonstrated that EPC
migration in response to VEGF was impaired in high
glucose-induced senescent EPCs, suggesting a poten-
tial mechanism by which induction of the senescent
state impairs EPC function.
The presence of elevated oxidised low density
lipoproteins (ox-LDL) observed in diabetics has also
been shown to reduce the number and impair function
of circulating EPC. Providing further support for the
link between diabetes and EPC senescence, Imanishi
et al. (2004) demonstrated that ox-LDL can induce
EPC senescence leading to EPC dysfunction. A further
study supports these findings, reporting that EPCs
from normal donors cultured in the presence of ox-
LDL underwent cell senescence associated with Akt
activation and that EPCs from diabetic patients
showed a similar phenotype to these ox-LDL induced
senescent EPCs (Rosso et al. 2006). Although senes-
cence was not specifically mentioned and instead
referred to as EPC dysfunction, Ji et al. (2015) showed
that ox-LDL decreased the proliferation, migration
Fig. 2 Metabolic diseases
accelerate the formation of
senescent cells in other
tissues
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and adhesion capacity of EPC. In addition, ox-LDL
treated EPCs displayed increased ROS production,
NADPH oxidase expression and activation of the NF-
kB pathway, a known regulator of the pro-inflamma-
tory secretome of senescent cells. An increase in
NADPH oxidase has also been reported in ox-LDL
induced cell senescence in macrophages (Wang et al.
2018).
Vascular endothelial cells
Vascular endothelial cells (EC) play an important role
in regulating vascular tone (via nitric oxide activity),
cellular adhesion and filtration, smooth muscle cell
proliferation and thromboresistance (resistance to
non-haemostatic blood clotting). As such, when
endothelial cells become dysfunctional, the biological
consequence can be multifaceted. Induction of cellular
senescence is likely one mechanism promoting
endothelial dysfunction.
High glucose levels associated with diabetes have
also been shown to promote EC senescence in vitro.
Culturing HUVECs under high glucose was shown to
induce HUVEC senescence and is again associated
with a reduction in NO synthesis (Zhong et al. 2010).
In this instance, co-incubation with L-arginine (a
substrate for NO synthesis) reduced the appearance of
senescent-like cells and increased NO production,
suggesting that administration of L-arginine could
improve vascular function during CVD. Arginase 1 is
an enzyme which catalyses the hydrolysis of arginine
to urea and ornithine. A recent study showed that
arginase 1 gene deletion or pharmacology inhibition
protected against induction of EC senescence in
diabetic mice (Shosha et al. 2018). Conversely,
arginase 1 overexpression or high glucose treatment
increased SA-b-Gal activity in cultured ECs, suggest-
ing that inhibition of arginase activity may be a
strategy for preventing premature senescence.
Another study demonstrated that high glucose-
induced EC senescence could be reduced through the
use of the drug Donepezil via SIRT1 activity (Zhang
et al. 2015). Interestingly, it appears that intermitted
high glucose rather than constant high glucose is more
likely to promote EC senescence (Maeda et al. 2015).
Intermitted high glucose induced EC senescence
involved the upregulated expression of p22phox, an
NADPH oxidase component, increasing superoxide.
Another study investigated the impact of insulin on
glucose-induced endothelial senescence in HUVECs
and human aortic endothelial cells, demonstrating that
physiological concentrations of insulin could delay the
appearance of senescent-like ECs under high glucose
conditions, associated with a reduction in ROS
generation and an increase in NO (Matsui-Hirai
et al. 2011).
High blood glucose levels can also lead to the
glycation of proteins, consequently disrupting their
normal function. In addition, advanced glycation end-
products (AGEs) may interact with membrane recep-
tors of cells that alter intracellular signalling and
promoting the production of pro-inflammatory cytoki-
nes and ROS (Singh et al. 2014). There have been a
limited number of studies which suggest that glycation
products may act as a trigger for inducing cell
senescence. For example, culturing early-passage
endothelial cells on glycated collagen was reported
to increase premature senescence associated with a
decrease in nitric oxide (NO) production (Chen et al.
2002). Furthermore, SA-b-Gal activity was elevated in
ECs of aortas derived from Zucker diabetic rats
compared to control rats. Interestingly, obesity is
known to impair vasodilation of blood vessels and
therefore blood flow (a CDV risk factor) by decreasing
NO production (Toda and Okamura 2013), suggesting
that obesity accelerated induction of senescent ECs
may contribute to this impairment. A number of other
studies have suggested that advanced AGEs play a role
in ‘‘endothelial dysfunction’’ although not necessarily
related to senescence induction (Goldin et al. 2006).
As with EPCs, there are also some indications to
suggest that ox-LDL may also accelerate EC senes-
cence. Rats fed on a high fat diet to establish a
hyperlipidemic model, resulted in increased plasma
lipids, endothelium-derived myeloperoxidase (MPO)
expression, EC senescence and endothelial dysfunc-
tion associated with a reduction in glycogen synthase 3
beta (GSK-3b) activity and p-b-catenin (Liu et al.
2015b). In vitro treatment of ECs with ox-LDL also
induced MPO expression and EC senescence, associ-
ated with a decrease in GSK-3b and p-b-catenin, thus
supporting their in vivo findings. Inhibition of MPO
reduced the number of senescent cells in vitro, sug-
gesting senescence induction in this instance is
partially mediated via the production of MPO-derived
hypochlorous acid (HOCl).
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Vascular smooth muscle cells
Vascular calcification, referring to the deposition of
calcium phosphate mineral in the intima or media of
arterial walls is a major risk factor in CVD as it leads to
reduced elasticity and compliance of arteries (Wexler
et al. 1996). The presence of diabetes is known to
accelerate arterial calcification, in which VSMCs
appear to transform into osteoblast-like cells, thought
to be mediated in part by high glucose levels (Chen
and Moe 2003; Tyson et al. 2003). Interestingly, a
number of studies have reported that VSMCs under-
going cell senescence adopt a pro-calcificatory phe-
notype. Microarray analysis of replicative senescent
VSMCs suggested that senescent VSMCs adopt a pro-
calcificatory phenotype associated with the repression
of matrix Gla protein (MGP), an inhibitor of calcifi-
cation and the up-regulation of bone morphogenetic
protein (BMP2), which promotes calcification (Burton
et al. 2009). These findings were supported by
Nakano-Kurimoto et al. (2009), who demonstrated
that replicative senescent VSMCs indeed undergo
calcification as determined by Alizarin red staining,
associated with increased expression of alkaline
phosphatase via runt-related transcription factor-2
(RUNX-2). It thus appears that senescent VSMCs
adopt a cell type specific senescent phenotype asso-
ciated with calcification (Burton et al. 2010).
Whilst there does not appear to be any studies
investigating whether AGEs can induce senescence in
VSMCs, there are a number of reports demonstrating
that AGEs induce calcification in VSMCs. Wang et al.
demonstrated that AGEs could promote human aortic
smooth muscle cell (HASMC) calcification through
activating NF-kB and downregulating IGF1R (Wang
et al. 2013). Adding further insight into a possible
mechanism of VSMC calcification, Wei et al. (2013)
showed that AGE-induced calcification in VSMC is
associated with enhanced Nox1 expression and con-
sequently the production of intracellular superoxide
anions. Although senescent cells are often associated
with NF-kB activation and elevated ROS, it cannot be
assumed that induction of the senescent state is the
primary mechanism promoting calcification in these
instances. Further work is required to fully evaluate
the possible link between AGEs, calcification and cell
senescence.
Kidney disease
High glucose levels associated with diabetes can result
in kidney damage (diabetic nephropathy) leading to
the build-up of waste fluids in the blood (Shahbazian
and Rezaii 2013). As with CVD, there is some
evidence suggesting that kidney damage may partially
be due to senescence induction. Verzola et al. (2008)
investigated whether cellular senescence could be a
mechanism promoting kidney damage in type 2
diabetic nephropathy (DN). Renal biopsies from
patients with type 2 DN showed a three-fold increase
in SA-b-Gal activity within the tubular compartment
of diabetic kidneys and an increase in p16 expression
in both tubules and podocytes compared to controls.
Furthermore, proximal tubule cells cultured under
high glucose reduced the proliferative capacity of
cells, increasing both SA-b-Gal staining and p16
indicative of cell senescence. Kitada et al. (2014) later
demonstrated using a type-1 diabetic mouse model,
that hyperglycaemia increases renal expression of p21
and SA-b-Gal staining in tubular epithelial cells in the
early stages of diabetic nephropathy. Again, cultured
human proximal tubular cells in high glucose elevated
the expression of senescence markers, whilst knock-
down of p21 or sodium glucose cotransporter (SGLT)
2 prevented senescence induction.
As with cardiovascular related cells, AGEs have
also been shown to induce premature senescence in
proximal tubular epithelial cells via activation of
endoplasmic reticulum stress (Liu et al. 2015a).
Blocking receptors for advanced glycation end-prod-
ucts (RAGE) reduced AGE-induced premature senes-
cence. In another study, Ikeda et al. (2011)
investigated the effects of AGEs in primary renal
proximal tubular epithelial cell (RPTECs) senescence
by modulating glyoxalase I (GLO1) which detoxifies
precursors (i.e. glycoxal) of AGEs. Aged GLO1
overexpressing transgenic rats showed reduced levels
of cell senescence associated with reduced accumula-
tion of renal AGEs. Furthermore, GLO1-transgenic
rats had reduced age-related interstitial thickening and
were protected against age-dependent decline in renal
function. Validating these in vivo findings in vitro, late
passage renal proximal epithelial cells showed ele-
vated senescence markers that were reduced in cells
overexpressing GLO1 or accelerated through GLO1
knockdown. Glyoxal has also been shown to induce
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cell senescence in fibroblasts and mesenchymal stem
cells (Larsen et al. 2012; Sejersen and Rattan 2007).
It thus appears that diabetes may promote kidney
disease by accelerating kidney ageing through prema-
ture induction of cell senescence. A number of studies
have looked at the possible link between cellular
senescence and kidney function decline associated
with ageing. Berkenkamp et al. (2014) investigated
age-related changes in tubular epithelial cells in young
and aged mice and in vitro. Kidneys from aged mice
showed more senescence markers (SA-b-Gal, p16,
cH2AX, Ki67) and an elevation in cyclin D1 com-
pared to youngmice. Although cyclin D1 is commonly
considered as a proliferation marker which was
expected to decline with age in this instance, cyclin
D1 has been reported as a marker of cell senescence,
possibly functioning to inhibit p21 degradation (Bur-
ton et al. 2007; Coleman et al. 2003). In another age-
related study focused on rat kidneys, Melk et al. (2003)
also reported that aged rats (9–24 months) also show a
72-fold increase in p16INK4A RNA expression, an
increase in SA-b-Gal staining within the epithelium,
but without a significant change in telomere length.
Cancer
Obesity is a well-known risk factor for the develop-
ment of a variety of different cancers, likely owing in
part to increased secretion of hormones into the
bloodstream leading to functional dysregulation in
recipient cells (Basen-Engquist and Chang 2011).
However, one interesting study has provided evidence
which suggests that obesity induces altered gut
microbial metabolites which can promote liver cancer
through cell senescence induction (Yoshimoto et al.
2013). Induction of obesity in mice altered the gut
microbiota leading to an elevation in the levels of the
gut bacterial metabolite, deoxycholic acid (DCA),
known to induce DNA damage. DCA was shown to
induce hepatic stellate cell (HSC) senescence associ-
ated with a pro-inflammatory tumour promoting
secretome that facilitated hepatocellular carcinoma
(HCC) development in the livers. Blocking DCA
production, reducing gut bacteria or inhibiting the
senescent secretome (IL1b absence) all prevented
HCC development. Research focused on obesity
induced cellular senescence and its role in promoting
cancer is at its infancy and it will interesting to see
what further developments are made within this field.
Therapeutic targeting of senescent cells
Senescent cells likely play a role in the development
and progression of metabolic diseases such as obesity
and diabetes, which in turn can lead to diabetes-
induced senescence and the formation of secondary
diseases such as CVD and kidney disease. Therefore,
therapeutically targeting senescent cells has great
potential for improving health (Gura˘u et al. 2018).
Such strategies may include (1) senescent cell pre-
vention, (2) senescent cell reversal, (3) inhibiting
aspects of the senescent phenotype and (4) senescent
cell elimination.
Inhibiting molecular pathways important for induc-
tion into cell senescence could prevent cells under
certain conditions (such as high glucose) from
becoming senescent. As mentioned above with regard
to EC senescence, this may include the use of drugs
which inhibit arginase 1 and SIRT1 activity. In
addition to preventing cell senescence, it may one
day be possible to reverse cell senescence. It has been
suggested that the use of resveratrol-related com-
pounds (resveralogues) can rescue cells from senes-
cence, but further research is required (Latorre et al.
2017). The third therapeutic approach is the inhibition
of the damaging components of the senescent pheno-
type, primarily the pro-inflammatory secretome. The
regulation of the senescent secretome has been
research extensively in recent years and an under-
standing of the molecular pathways involved has
enabled its inhibition via drugs (reviewed in Malaquin
et al. 2016). As an example of the potential benefits,
findings from one study suggested that inhibition of
senescent secretome in mice reduces frailty in old age
(Xu et al. 2015b). The elimination of senescent cells
by induction of cell death has provided the most
convincing evidence in mice that senescent cells play
a role in diseases and that their removal can be
beneficial to health (reviewed in McHugh and Gil
2018). As such, there have been several drugs in recent
years that have been identified or created which can
specifically kill senescent cells (Childs et al. 2017; de
Keizer 2017; Mun˜oz-Espı´n et al. 2018; Soto-Gamez
and Demaria 2017). In addition to the use of pharma-
cological drugs, it may be possible to use our own
immune system to target the removal of senescent
cells in a similar manner that immunotherapy is now
being used to target some cancers (Burton and
Stolzing 2018).
123
Biogerontology (2018) 19:447–459 455
Currently the use of drugs is justified only when a
disease has manifested and is problematic. In addition,
there are often specific drugs for specific diseases. If
many different diseases have a common underlying
cause, such as cell senescence, it may one day be
possible to treat many different diseases with a single
drug. However, rather than waiting for a disease to
present itself, intermittent removal of senescent cells
throughout our lifetime could be utilised as a preven-
tative measure, ensuring long and healthy lives.
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